News

Enlarge image

PoliticsEU

New president fires against EU

25.06.2013 - Sanofi’s CEO Christopher Viehbacher has been elected head of Europe’s pharma lobby organisation EFPIA. He started off with threatening EU politicians.

Christopher A. Viehbacher, Chief Executive Officer of Sanofi, was elected President of EFPIA, the European Federation of Pharmaceutical Industries and Associations, for a 2-year term. Viehbacher, holding both German and Canadian nationalities, took the chance after the election on June 24 to take up a stance on EU politics. The quarrel is about the European Medicine Agency’s (EMA) strategy to make drug development more transparent by disclosing data from clinical studies. The EMA hopes that the released data on already approved drugs could spur research in general. The industry, however, believes competitors from the biologics field may gain valuable information and thus feels bullied. Speaking of his very own Sanofi, Viehbacher argues in a Reuters release: „If I was to say where would I put the next euro of investment, I would say either the next euro of investment would go to the United States or to emerging markets.“ The data in question also includes information that may help competitors in the field, Viehbacher fears that other companies like GSK or Roche got less exercised on the issue. They plan to open the corresponding raw data files for qualified researchers.

Beyond that discussion, Viehbacher also identified other construction sites, The EFPIA head urged: „Given the chronic deficits of healthcare systems, we must work differently, build collaborative policies and combine our strengths at both national and European levels. As we want Healthcare to be a growth engine for Europe, our industry must focus on three priorities: patient access, science & innovation and competitiveness.” Viehbacher follows Andrew Witty from UK’s GlaxoSmithKline. Joining him at the head of the EFPIA board will be two newly elected Vice Presidents, Roch Doliveux, Chief Executive Officer of UCB, and Joseph Jimenez, Chief Executive Officer of Novartis.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/new-president-fires-against-eu.html

Nuclear medicineNorwayFrance

28.06.2016 Nordic Nanovector has teamed up with Areva Med to develop a treatment for leukaemia. The compound in question is a lead-212 conjugated anti-CD37 antibody.

European UnionUKEU

24.06.2016 After the British people voted in favour of leaving the European Union, the industry is grappling with the profound impact this will likely have. Representatives from biotech industry, research and policits have expressed their concerns and hopes on the upcoming Brexit.

Investment FundUKIrelandEULuxembourg

24.06.2016 UK investment vehicle Malin has secured another €70m to invest in innovation and research across the European life sciences. The European Investment Bank will provide a debt facility over a period of seven years.

ImmunotherapyFranceEU

22.06.2016 TxCell has jumped on its option for a licensing agreement with the Weizmann Institute of Science’s tech transfer arm after it was granted a far-reaching patent for redirected, genetically engineered T regulatory cells by the EPO.

Clinical TrialsUK

21.06.2016 Circassia suffered a severe blow when its cat allergy immunotherapy failed to outcompete the placebo in a Phase III trial. The company’s shares, listed in London, plunged to a third of its previous value.

R&DSwitzerlandUK

16.06.2016 With support from the Medicines for Malaria Venture and Gates Foundation, Novartis will tackle resistant malaria with a new compound.

FinancingEUNetherlands

14.06.2016 European specialist investment firm Gilde Healthcare has closed its €250m fund for later stage and growth capital in medtech, digital health and therapeutics. The oversubscribed fund will invest in both Europe and North America.

AwardEUPortugalGermanyDenmarkFrance

09.06.2016 Exceptional inventors from all over Europe have been honoured with the European Inventor Award 2016. With the award, the European Patent Office recognises the achievements of inventors from Denmark, France, Germany, the Netherlands, the UK and the US.

Personalised medicineUK

08.06.2016 Finding a treatment for depression that is well-tolerated and effective is difficult and time-consuming. UK scientists have now developed a blood test to predict whether common antidepressants will work in a patient.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS (CH)0.04 CHF33.33%
  • MOLOGEN (D)2.90 EUR14.62%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • SILENCE THERAPEUTICS (UK)103.00 GBP-8.85%
  • ALLERGY THERAPEUTICS (UK)19.00 GBP-8.61%
  • VERNALIS (UK)34.75 GBP-6.71%

TOP

  • THERAMETRICS (CH)0.04 CHF100.0%
  • IMMUPHARMA (UK)34.00 GBP19.3%
  • ADDEX (CH)2.72 CHF17.2%

FLOP

  • SARTORIUS (D)67.94 EUR-72.2%
  • CIRCASSIA LIMITED (L)92.50 GBP-65.3%
  • VALNEVA (F)2.10 EUR-36.7%

TOP

  • KARO BIO (S)25.70 SEK1709.9%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)11.33 EUR509.1%

FLOP

  • BB BIOTECH (D)40.24 EUR-84.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.35 SEK-78.4%
  • EVOCUTIS (UK)0.05 GBP-77.3%

No liability assumed, Date: 29.06.2016